Thursday, September 24, 2026
← Back to archivePolicy
Policy•STAT News•Sep 24, 2026
Opinion: Measles almost killed me. Now I’m a doctor — and I’m scared of what’s happening
background ▾
- •U.S. measles cases in 2025 have already surpassed the entire 2024 case count with four deaths in Pennsylvania; childhood MMR vaccination rates have declined to 92.4%, falling below the 95% threshold needed to prevent community transmission
- •Recent federal changes to vaccine recommendation processes have created public confusion and hesitation among both patients and healthcare providers, compounding access barriers that already limit vaccination uptake
- •Healthcare providers and public health officials must coordinate transparent, evidence-based messaging and address structural access barriers (insurance, healthcare availability, trusted communication channels) as the primary levers to reverse declining vaccination rates before holiday season amplifies transmission
MMR vaccine
→ Read original articlePolicy•STAT News•Sep 23, 2026
White House plan to increase control of NIH grants appears ‘dead’
background ▾
- •A planned executive order to establish a politically-appointed commission with veto power over NIH grants has been effectively withdrawn due to bipartisan congressional pressure, preserving the merit-based peer review system for now.
- •This marks the latest in a series of OMB attempts to expand political control over federal research funding, including prior initiatives on multiyear funding structures, spending delays, and Federal Acquisition Regulation rewrites—most of which were curbed by Congress.
- •Monitor whether the Trump administration pursues alternative mechanisms to influence NIH grant decisions and whether Congress maintains its bipartisan coalition to defend research funding independence in the 2027 appropriations cycle.
Policy•Fierce Biotech•Sep 23, 2026
Trump's Department of War bets $47M on Flagship biotechs to develop countermeasures
background ▾
- •The DoW's OnTarget program commits $47M over five years to Flagship's portfolio, focusing on broad-spectrum countermeasures, precision delivery, toxin neutralization, immune enhancement, and AI/ML optimization—signaling heightened government prioritization of biological defense infrastructure.
- •Apriori Bio's Octavia platform and Prologue's Delve platform are being leveraged for predictive viral evolution and immunomodulatory protein discovery, respectively, positioning these early-stage Flagship companies as strategic assets in the federal medical countermeasure ecosystem.
- •Watch for: regulatory pathways for these government-funded countermeasures, potential dual-use commercialization strategies, and whether additional Flagship portfolio companies are incorporated into the program's expansion phase.
Flagship PioneeringApriori BioPrologue Medicines
→ Read original articlePolicy•Endpoints News•Sep 23, 2026
FDA adcomm votes in favor of benefit-risk of Grail’s cancer test
background ▾
- •FDA advisory committee endorsed Galleri's benefit-risk profile despite documented efficacy and utility concerns, positioning the test for potential approval
- •Committee's hesitation signals the FDA may condition approval on real-world evidence generation or restricted labeling rather than unrestricted screening indication
- •Monitor final FDA decision timeline and label scope—approval restricted to symptomatic patients or high-risk populations would substantially impact commercial potential versus asymptomatic screening claims
GrailGalleri
→ Read original articlePolicy•Endpoints News•Sep 23, 2026
Chinese vaccine scandal leads to life sentence; Flagship wins defense contract
background ▾
- •Life sentence imposed on Changsheng Biotechnology former chair for vaccine scandal—demonstrates severe criminal penalties for manufacturing violations in China
- •Case reflects broader regulatory crackdown on vaccine safety lapses and manufacturing integrity in China, likely to influence global perception of Chinese biotech manufacturing standards
- •Incident may accelerate tighter oversight of Chinese vaccine and biologics manufacturers by international regulators and spur additional compliance investments
Changsheng BiotechnologyVaccine (unspecified)
→ Read original articleMarket Access
Market Access•Fierce Biotech•Sep 24, 2026
Lilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCare
background ▾
- •Lilly's $3.25B milestone structure signals confidence in InnoCare's discovery platform, but lack of target disclosure prevents assessment of actual deal value or competitive risk
- •InnoCare's emerging TYK2 program positions it as a rival to BMS/Takeda in autoimmune space, potentially justifying Lilly's interest in the partnership
- •Strategic question: whether Lilly is acquiring early discovery assets or closer-to-clinic programs, and whether this reflects Lilly's need to diversify beyond GLP-1-driven cash or genuine platform conviction
Eli LillyInnoCare PharmaBristol Myers SquibbVAV1 degraderTYK2 inhibitororelabrutinib
→ Read original articleMarket Access•Fierce Biotech•Sep 23, 2026
Boehringer adds $250M to value of Variant pact by expanding into cardiovascular disease
background ▾
- •Boehringer is committing an additional $250M+ to Variant Bio to expand AI-driven target discovery into cardiovascular disease, signaling confidence in genomics-enabled drug discovery as a core R&D strategy
- •The collaboration pairs Variant's multi-population genomic and phenotypic data integration with Boehringer's deep cardiovascular expertise, reflecting a trend toward outsourced AI/target discovery partnerships for large pharma
- •Watch for clinical progression of targets identified through this collaboration and whether Boehringer successfully converts genomically-validated targets into differentiated first-in-class cardiovascular candidates
Boehringer IngelheimVariant BioNovo NordiskJardiancePradaxaTwynsta
→ Read original articleMarket Access•Fierce Biotech•Sep 23, 2026
Enveda reaps $311M series E to feed ambition to become a ‘household name’
background ▾
- •Enveda has now raised $311M Series E on top of $150M Series D (September 2025) and $130M Series C (November 2024), demonstrating strong investor confidence despite unproven late-stage potential
- •ENV-294 showed encouraging Phase 1b data (68% reduction in eczema/severity by Day 28, 85% by Day 42) and is advancing to Phase 2a in atopic dermatitis and asthma
- •ENV-308, positioned as an exercise-mimetic to support weight loss maintenance post-GLP-1, and ENV-6946 for IBD represent expansion into competitive therapeutic areas where clinical proof-of-concept remains early
Enveda TherapeuticsENV-294ENV-308ENV-6946
→ Read original articleMarket Access•Endpoints News•Sep 23, 2026
Baby KJ's gene-editing drug cost $1.65M to make, Fyodor Urnov says
background ▾
- •First-in-world personalized gene-editing therapy cost $1.65M to manufacture, establishing a critical benchmark for ultra-rare, patient-specific treatments
- •This cost structure raises urgent questions about how payers will reimburse patient-specific genetic medicines and whether manufacturing economies can ever be achieved for truly bespoke therapies
- •Watch for regulatory guidance on pricing and reimbursement frameworks for individualized gene therapies, and for evidence of manufacturing cost reduction as the field matures
Market Access•Endpoints News•Sep 23, 2026
Enveda raises its third megaround for I&I and weight maintenance drug candidates
background ▾
- •Enveda has secured a third major funding round, indicating sustained capital availability for natural product-derived drug discovery despite broader biotech funding pressures
Enveda Biosciences
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Sep 24, 2026
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
background ▾
- •Miv-cel demonstrated durable clinical benefit out to 12 months in SPS with an exceptionally clean safety profile (zero high-grade cytokine release syndrome, ICANS, or IEC-HS cases), directly contrasting with reported safety setbacks in competing Big Pharma autoimmune CAR-T programs
- •92% of SPS patients remained free of chronic immunotherapies at one year post-treatment, with 67% of those previously requiring walking aids no longer needing assistance—representing a potential paradigm shift for a progressive, currently off-label-only treated disease
- •Watch for FDA action on Kyverna's rolling submission completion in Q4 2024 and potential regulatory approval timeline; monitor for any emerging safety signals in the broader autoimmune CAR-T field and competitive positioning against other pipeline candidates
Kyverna Therapeuticsmiv-cel (mivocabtagene autoleucel)
→ Read original articleClinical Trials•Endpoints News•Sep 23, 2026
Roche kidney drug's Phase 3 win sets up path to accelerated approval
background ▾
- •Roche's kidney drug achieved Phase 3 efficacy, clearing a key hurdle toward accelerated approval in a crowded market with five established competitors
- •The competitive landscape is intensifying in kidney disease treatment, suggesting commercial success will depend on differentiation and payer positioning rather than first-mover advantage
RocheNovartisCalliditas
→ Read original articleClinical Trials•STAT News•Sep 24, 2026
Opinion: STAT+: A moment of reckoning for preventive cardiology and the precision medicine revolution
background ▾
- •Pelacarsen achieved Lp(a) lowering but failed to reduce cardiovascular events—a critical disconnect between biomarker and clinical endpoints that challenges the therapeutic strategy and may complicate regulatory/payer approval pathways
- •Back-to-back failures of biologics (ziltivekimab and pelacarsen) to convert target engagement into clinical outcomes signal a broader validation crisis in precision medicine approaches for cardiology
- •Watch for regulatory feedback on pelacarsen's approvability and whether efficacy expectations will shift; also monitor impact on funding and investor confidence in biomarker-driven cardiology programs industry-wide
NovartisNovo Nordiskpelacarsenziltivekimab
→ Read original articleClinical Trials•Fierce Biotech•Sep 23, 2026
Immunovant ends cutaneous lupus program after phase 2 flop
background ▾
- •IMVT-1402 failed its primary endpoint in Phase 2 CLE, with no statistically significant improvement over placebo at Week 12 on the CLE area and severity scale
- •Competitive landscape dominated by non-FcRn mechanisms (anti-BDCA2, TLR7/8 inhibitors, type I IFN receptor inhibitors) appears to have influenced the discontinuation decision alongside clinical results
- •Monitor IMVT-1402 advancement in remaining five indications, particularly Graves' disease and myasthenia gravis where FcRn blockade may have stronger mechanistic rationale
ImmunovantRoivantJohnson & JohnsonIMVT-1402Imaavylitifilimab
→ Read original articleClinical Trials•Endpoints News•Sep 23, 2026
Roivant reports Phase 2b lupus failure for an FcRn drug
background ▾
- •FcRn inhibitor failed Phase 2b primary endpoints in lupus, eliminating a lead autoimmune asset from Roivant's pipeline
- •Raises mechanistic questions about FcRn inhibition efficacy in lupus despite theoretical rationale for the target
- •Watch for Roivant's strategic response: whether the company will explore alternative indications, modify the program design, or reallocate resources to other pipeline candidates
RoivantFcRn inhibitor
→ Read original article